Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24086642 | 0.87 | ESR1 (0.34) | RIPK1ESR1 | |
| SCHEMBL13020832 | 0.83 | ESR1 (0.32) | RIPK1ESR1 | |
| SCHEMBL24419417 | 0.83 | ESR1 (0.38) | ESR1DPP4 | |
| SCHEMBL13547936 | 0.82 | CACNA1H (0.37) | — | |
| SCHEMBL12866865 | 0.81 | ESR1 (0.46) | RIPK1ESR1THRATHRB | |
| SCHEMBL25039104 | 0.81 | ESR1 (0.37) | ESR1DPP4SLC6A2 | |
| SCHEMBL25039210 | 0.79 | RIPK1 (0.45) | RIPK1MAOB | |
| SCHEMBL13547868 | 0.78 | DBH (0.41) | ESR1TAAR1 | |
| SCHEMBL12867251 | 0.78 | KCNH2 (0.35) | — | |
| SCHEMBL1912679 | 0.77 | IDO1 (0.41) | ESR1THRATHRBSLC6A2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230399320-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | Pelemed Co., Ltd. (UA) | 2023-12-14 | — | — | US | disclosed |
| US-20230399320-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | Pelemed Co., Ltd. (UA) | 2023-12-14 | — | — | US | disclosed |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | REDHILL BIOPHARMA LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | REDHILL BIOPHARMA LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11633385-B2 | Combination compositions for treatment of cancer | REDHILL BIOPHARMA LTD. (IL) | 2023-04-25 | — | — | US | disclosed |
| US-20210369754-A1 | INHIBITOR OF SPHINGOSINE KINASE 2 FOR TREATING EBOLA | REDHILL BIOPHARMA LTD (IL) | 2021-12-02 | — | — | US | disclosed |
| US-11090325-B2 | Compositions for treating ebola virus infection | REDHILL BIOPHARMA LTD. (IL) | 2021-08-17 | — | — | US | disclosed |
| US-20210128538-A1 | COMBINATION COMPOSITIONS FOR TREATMENT OF CANCER | REDHILL BIOPHARMA LTD (IL) | 2021-05-06 | — | — | US | disclosed |
| US-20090221689-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA INC. | 2009-07-02 | — | — | US | disclosed |
| US-7491695-B2 | Therapy for endocrime disorders; gastrointestinal disorders; cardiovascular disorders; obesity; central nervous system disorders; antiproliferative agents ; using growth hormone secretagogue receptor | TRANZYME PHARMA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-7476653-B2 | Using growth hormone secretagague receptors; endocrime disorders; gastrointestinal disorders; cardiovascular disorders; central nervous system disorders; antiproliferative agents; antiinflammatory agents | TRANZYME PHARMA, INC. (CA) | 2009-01-13 | — | — | US | disclosed |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-7338961-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221689-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | RIPK1 1856/4885ESR1 365/4885MAOB 3458/4885 |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | GHSR, GHRHR, GIPR | RIPK1 2459/4885ESR1 534/4885MAOB 2868/4885 |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | RIPK1 158/4885ESR1 4551/4885MAOB 2399/4885 |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | RIPK1 2290/4885ESR1 4759/4885MAOB 3575/4885 |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | SPHK2, SPHK1, S1PR2 | RIPK1 462/4885ESR1 4857/4885MAOB 1033/4885 |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | RIPK1 55/4885ESR1 4530/4885MAOB 2658/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | RIPK1 3349/4885ESR1 3826/4885MAOB 198/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | RIPK1 2944/4885ESR1 4773/4885MAOB 2323/4885 |
| US-11633385-B2 | Combination compositions for treatment of cancer | KRAS, TPMT, CYP2D6 | RIPK1 4349/4885ESR1 1193/4885MAOB 503/4885 |
| US-20210128538-A1 | COMBINATION COMPOSITIONS FOR TREATMENT OF CANCER | KRAS, TPMT, CYP2D6 | RIPK1 4349/4885ESR1 1193/4885MAOB 503/4885 |
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | RIPK1 1856/4885ESR1 365/4885MAOB 3458/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | RIPK1 2459/4885ESR1 534/4885MAOB 2868/4885 |
| US-20210369754-A1 | INHIBITOR OF SPHINGOSINE KINASE 2 FOR TREATING EBOLA | SPHK2, SPHK1, S1PR2 | RIPK1 462/4885ESR1 4857/4885MAOB 1033/4885 |
| US-20230399320-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | ZC3HAV1, COPB1, CNBP | RIPK1 1403/4885ESR1 4851/4885MAOB 3851/4885 |
| US-11090325-B2 | Compositions for treating ebola virus infection | NEFM, EIF2AK2, IRF3 | RIPK1 3825/4885ESR1 4810/4885MAOB 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.